Skip to main content

Table 3 Effect of A. hydaspica AHE fraction on hematological parameters

From: Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats

Treatment (mg/kg) RBC (106/μl) WBC (103/μl) Hb (g/Dl) PCV (%) MCV (fL) MCH (pg) MCHC (g/dL) Neutrophil (103/μl) Lymphocytes (103/μl) Platelets (103/mm3)
Control 8.01 ± 0.33 9.12 ± 0.51 13.13 ± 0.87 43.9 ± 1.22 73.11 ± 2.54 16.11 ± 1.11 29.57 ± 2.50 34.53 ± 2.71 22.11 ± 2.56 709 ± 3.22
DOX 4.61 ± 0.37a 5.11 ± 0.44a 10.08 ± 0.79a 22.65 ± 1.45a 59.98 ± 2.68a 10.20 ± 0.99a 19.89 ± 1.98a 21.10 ± 2.54a 47.81 ± 2.76a 386 ± 3.29a
AHE alone 8.10 ± 0.41b 9.19 ± 0.49b 13.23 ± 0.81b 45.11 ± 1.24b 74.01 ± 2.35b 16.55 ± 1.01b 29.9 ± 2.11b 35.11 ± 2.67b 21.21 ± 2.88b 714 ± 3.11b
DOX+ AHE (200) 6.01 ± 0.39a*,c** 6.67 ± 0.43a,b,c 11.01 ± 0.76a**,b,c 30.12 ± 1.56a,b,c 63.9 ± 2.60a,c* 12.87 ± 0.98a,b**,c* 22.34 ± 1.89a,c** 24.41 ± 2.71a,c** 39.65 ± 2.78a*,b,c** 498 ± 3.21a,b,c
DOX+ AHE (400) 7.95 ± 0.42b 8.98 ± 0.47b 12.80 ± 0.79b 39.50 ± 1.60b 68.99 ± 2.22b 14.98 ± 1.06b 27.65 ± 2.02b 30.22 ± 2.45b 27.32 ± 2.81a*,b 667 ± 3.78a,b
DOX+ Sily 7.96 ± 0.40b 8.97 ± 0.45b 12.88 ± 0.81b 39.23 ± 1.71b 68.56 ± 2.44b 15.08 ± 1.04b 27.9 ± 2.00b 31.01 ± 2.66b 27.50 ± 2.56a*,b 670 ± 3.66a,b
  1. Data expressed as mean ± SEM (n = 6)
  2. asignificant difference Vs. Control group at p < 0.0001
  3. bsignificant difference Vs. DOX-treated group at p < 0.0001
  4. csignificant difference of DOX + AHE (200 mg/kg) treated group Vs. DOX + AHE (400 mg/kg) treated group at p < 0.001
  5. *, **indicate significance at p < 0.05 and p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin
\